From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers

Abstract

Frontotemporal dementia (FTD) is an increasingly recognized cause of dementia. This review discusses the different FTD clinical syndromes and frontotemporal lobar degeneration (FTLD) pathological correlates as well as new genetic and proteomic findings that have added to our understanding of FTLD pathogenesis. Various diagnostic modalities including the use of biomarkers will also be addressed. Finally we will highlight future directions in the FTD field. More research is needed to elucidate the cellular mechanisms of neurodegeneration in FTLD and improve clinical diagnostic capabilities.

Declaration of interest: Dr. Hu may accrue revenue in the future on patents on Alzheimer's disease and frontotemporal lobar degenerations submitted by Emory University wherein he is Inventor. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.